PROMIS pediatric measures in pediatric oncology: Valid and clinically feasible indicators of patient-reported outcomes
PROMIS pediatric measures in pediatric oncology: Valid and clinically feasible indicators of patient-reported outcomes
复制标题
DOI：
10.1002/pbc.24233
复制
发表时间：
2013-03-01
影响因子：
3.2
通讯作者：
DeWalt, Darren A.
中科院分区：
文献类型：
--
作者：
Hinds, Pamela S.;Nuss, Suzanne L.;DeWalt, Darren A.
背景确定癌症儿童和青少年以电子方式完成NIH赞助的PROMIS儿科测量的能力，以及儿科肿瘤学测量(完整题库和简短表格)的初步有效性估计将有助于我们了解癌症治疗对这些年轻患者的影响。程序：在一项横断面研究设计中，共有203名8至17岁的青少年接受了8项PROMIS儿科测量，以确定已知组的效度。在完成全部或大部分项目的200人中，略占多数的是男性(55.5%)和白人(54%)。患者要么正在接受癌症治疗(n=93)，要么在癌症治疗后存活(n=107)。测量是在与研究人员面对面互动的过程中使用计算机界面完成的。结果203名受试者中只有3人没有完成PROMIS儿科测量。根据假设，接受治疗的参与者在父母报告的临床指标(血细胞计数、疲劳和食欲)以及七项自我报告指标(抑郁、焦虑、同伴关系、疼痛干扰、疲劳、上肢功能和行动能力)上与生存参与者有显著差异(更差)。女性报告的疲倦、愤怒和疼痛干扰比男性更严重。在对潜在的混杂变量进行调整后，积极治疗的患者报告的更糟糕的结果仍然存在。结论8~17岁接受癌症治疗或存活的儿童和青少年可在门诊就诊或住院期间使用计算机界面完成多项儿科护理措施。研究结果确立了儿童肿瘤学中PROMIS儿科措施的已知群体有效性。儿科血癌2013；60：402-408。(C)2012年威利期刊公司。
Background Establishing the ability of children and adolescents with cancer to complete the NIH-sponsored PROMIS pediatric measures electronically and the preliminary validity estimates of the measures (both full item banks and short forms) in pediatric oncology will contribute to our knowledge of the impact of cancer treatment on these young patients. Procedures A total of 203 8- to 17-year olds were administered eight PROMIS pediatric measures in a cross-sectional study design to establish known-group validity. Of the 200 who completed all or most of the items, a slight majority were male (55.5%) and white (54%). Patients were either undergoing treatment for cancer (n = 93) or in survivorship following treatment for cancer (n = 107). Measures were completed using computer interface during an in-person interaction with researchers. Results Only 3 of 203 participants did not complete the PROMIS pediatric measures. As hypothesized, participants in treatment were significantly different (worse) on parent-reported clinical indicators (blood counts, fatigue, and appetite) and on seven self-reported measures (depression, anxiety, peer relationships, pain interference, fatigue, upper extremity function, and mobility) from participants in survivorship. Females reported worse fatigue, anger, and pain interference than males. Worse patient-reported outcomes for patients in active treatment persisted after adjusting for potential confounding variables. Conclusions Children and adolescents in treatment for cancer or in survivorship and ranging from 8 to 17 years of age can complete multiple PROMIS pediatric measures using a computer interface during an outpatient clinic visit or inpatient admission. Findings establish known-group validity for PROMIS pediatric measures in pediatric oncology. Pediatr Blood Cancer 2013; 60: 402-408. (C) 2012 Wiley Periodicals, Inc.